[EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015005901A1
公开(公告)日:2015-01-15
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
A direct link between the Passerini reaction and α-lactams
作者:István Lengyel、Victor Cesare、Tony Taldone
DOI:10.1016/j.tet.2003.11.067
日期:2004.1
α-Lactams (aziridinones) can function to replace two of the three reactants, the oxo-compound and the isonitrile, in the Passerini reaction. Four α-lactams (5a-d) were reacted with mono- and dicarboxylic acids of positive pKa values to give 2-acyloxycarboxamides (4) and bis-2-acyloxycarboxamide products 12 and 13, respectively. The same compounds were also prepared via the Passerini reaction. Acids
α-内酰胺(叠氮ino烷)可以在Passerini反应中取代三种反应物中的两种,即氧代化合物和异腈。使四个α-内酰胺(5a - d)与正p K a值的单羧酸和二羧酸反应,分别得到2-酰氧基羧酰胺(4)和双-2-酰氧基羧酰胺产物12和13。还通过Passerini反应制备了相同的化合物。p K a p为负的酸将α-内酰胺脱羰,生成铵盐。反应的主要路径取决于p K a 酸成分,α-内酰胺的反应性和反应条件。
HEPATITIS C VIRUS INHIBITORS
申请人:BRISTOL-MAYERS SQUIBB COMPANY
公开号:US20160199355A1
公开(公告)日:2016-07-14
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.